Article
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Molecular cancer therapeutics - 1 Jan 2009
Sakurama Kazufumi, Noma Kazuhiro, Takaoka Munenori, Tomono Yasuko, Watanabe Nobuyuki, Hatakeyama Shinji, Ohmori Osamu, Hirota Seiichi, Motoki Takayuki, Shirakawa Yasuhiro, Yamatsuji Tomoki, Haisa Minoru, Matsuoka Junji, Tanaka Noriaki, Naomoto Yoshio
Abstract excerpt
Focal adhesion kinase (FAK) is often up-regulated in a variety of malignancies, including gastrointestinal stromal tumor (GIST), and its overexpression seems to be associated with tumor progressiveness and poor prognosis. GIST is well known to have a mutation to c-KIT; thus, a specific c-KIT inhibitor (imatinib) is recognized as the first-line chemotherapy for GIST, although a certain type of c-KIT mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.